Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

1. Know the Health Effects of Cannabis

Know the Health Effects of Cannabis Mental Health Daily or near-daily use of cannabis can contribute to dependence and mental health problems over time. Know the Health Risks of Cannabis Driving Cannabis can impair your motor coordination, judgment and other skills required for safe driving. Respiratory Effects Toxic and carcinogenic chemicals found in tobacco smoke are also found in cannabis smoke, and can affect the lungs and airways. Pregnancy Substances in cannabis are transferred from (...) mother to child and can affect your baby. Not using cannabis if pregnant or breastfeeding is the safest option. Stay Informed ccsa.ca/cannabis canada.ca/cannabis Edible Cannabis Consuming too much THC can lead to over-intoxication, which includes intense anxiety, vomiting and symptoms of psychosis (paranoia). Cannabis Extracts Cannabis extracts with high THC content increase the risk of over- intoxication and addiction.

2019 Canadian Centre on Substance Abuse

2. Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products

Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Edible Cannabis (or Edibles) Edible cannabis (or edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds (...) found in cannabis that can affect your mind and body when consumed. THC, or tetrahydrocannabinol, is a cannabinoid that makes an individual high, euphoric and intoxicated. CBD (cannabidiol) is a non-intoxicating cannabinoid that might have some therapeutic benefit, but more research is needed to confirm its potential medical use. Edible cannabis comes in a wide range of products. 1 Although some edible cannabis products might look like normal food items, they are not food; these products

2019 Canadian Centre on Substance Abuse

3. 7 Things You Need to Know about Edible Cannabis

7 Things You Need to Know about Edible Cannabis www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 7 Things You Need to Know about Edible Cannabis What Is Edible Cannabis? Edible cannabis products (edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds found in cannabis that can affect your mind and body when consumed. THC (tetrahydrocannabinol (...) ) is a cannabinoid that makes an individual euphoric and intoxicated (or high). CBD (cannabidiol) is a non-intoxicating cannabinoid that might have some therapeutic benefit, although more research is needed to confirm its potential medical use. There is a wide range of edible cannabis products. Although some edible cannabis products might look like normal food items, they are not food and are not intended to provide any nutritional value. Edible cannabis products provide an alternative method of cannabis

2019 Canadian Centre on Substance Abuse

4. Edibles, Extracts and Topicals: A Primer on the New Cannabis Products

Edibles, Extracts and Topicals: A Primer on the New Cannabis Products www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Edible Cannabis, Cannabis Extracts and Cannabis Topicals: A Primer on the New Cannabis Products Edible Cannabis (or Edibles) Edible cannabis (or edibles for short) are products containing cannabinoids that you eat or drink. Cannabinoids are chemical compounds found in cannabis (...) that can affect your mind and body when consumed. THC, or tetrahydrocannabinol, is a cannabinoid that makes an individual high, euphoric and intoxicated. CBD (cannabidiol) is a non-intoxicating cannabinoid that might have some therapeutic benefit, but more research is needed to confirm its potential medical use. Edible cannabis comes in a wide range of products. 1 Although some edible cannabis products might look like normal food items, they are not food; these products are not intended to provide any

2019 Canadian Centre on Substance Abuse

5. Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning

Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more noticeable cognitive impairment. • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest (...) predictors of cognitive impairment. However, it is unclear which comes first — whether cognitive impairment leads to early onset cannabis use or whether beginning cannabis use early in life causes a progressive decline in cognitive abilities. • Regular cannabis use is associated with altered brain structure and function. Once again, it is currently unclear whether chronic cannabis exposure directly leads to brain changes or whether differences in brain structure precede the onset of chronic cannabis use

2019 Canadian Centre on Substance Abuse

6. Pharmacotherapy for the Treatment of Cannabis Use Disorder

Pharmacotherapy for the Treatment of Cannabis Use Disorder Management Briefs eBrief-no151 -- Pharmacotherapy for the Treatment of Cannabis Use Disorder Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no151 -- Pharmacotherapy for the Treatment of Cannabis Use Disorder Health Services Research & Development Management eBrief no. 151 » Issue 151 April 2019 The report is a product (...) of the VA/HSR&D Evidence Synthesis Program. Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review Social, medical, and legal acceptance of cannabis has grown dramatically over the last 15 years, and cannabis use — for medical and recreational purposes — also has increased. From 2002 to 2012, the prevalence of daily cannabis use in the United States increased from 1.3 to 2.1%. Along with an increase in the acceptance and use of cannabis, the potency of cannabis available

2019 Veterans Affairs - R&D

7. Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning

Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more noticeable cognitive impairment. • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest (...) predictors of cognitive impairment. However, it is unclear which comes first — whether cognitive impairment leads to early onset cannabis use or whether beginning cannabis use early in life causes a progressive decline in cognitive abilities. • Regular cannabis use is associated with altered brain structure and function. Once again, it is currently unclear whether chronic cannabis exposure directly leads to brain changes or whether differences in brain structure precede the onset of chronic cannabis use

2019 Canadian Centre on Substance Abuse

8. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. (PubMed)

Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Little is known about the relative harms of edible and inhalable cannabis products.To describe and compare adult emergency department (ED) visits related to edible and inhaled cannabis exposure.Chart review of ED visits between 1 January 2012 and 31 December 2016.A large urban academic hospital in Colorado.Adults with ED visits with a cannabis-related International Classification of Diseases, Ninth or 10th (...) Revision, Clinical Modification (ICD-9-CM or ICD-10-CM), code.Patient demographic characteristics, route of exposure, dose, symptoms, length of stay, disposition, discharge diagnoses, and attribution of visit to cannabis.There were 9973 visits with an ICD-9-CM or ICD-10-CM code for cannabis use. Of these, 2567 (25.7%) visits were at least partially attributable to cannabis, and 238 of those (9.3%) were related to edible cannabis. Visits attributable to inhaled cannabis were more likely

2019 Annals of Internal Medicine

9. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia (Full text)

An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia In this experimental randomized placebo-controlled 4-way crossover trial, we explored the analgesic effects of inhaled pharmaceutical-grade cannabis in 20 chronic pain patients with fibromyalgia. We tested 4 different cannabis varieties with exact knowledge on their [INCREMENT]-tetrahydrocannabinol (THC) and cannabidiol (CBD) content: Bedrocan (22.4-mg THC, <1-mg (...) than placebo on spontaneous or electrical pain responses, although more subjects receiving Bediol displayed a 30% decrease in pain scores compared to placebo (90% vs 55% of patients, P = 0.01), with spontaneous pain scores correlating with the magnitude of drug high (ρ = -0.5, P < 0.001). Cannabis varieties containing THC caused a significant increase in pressure pain threshold relative to placebo (P < 0.01). Cannabidiol inhalation increased THC plasma concentrations but diminished THC-induced

2019 EvidenceUpdates PubMed

10. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Seizures may be reduced in some severe drug-resistant epilepsies by a cannabis derivative Discover Portal Discover Portal Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol to their treatment may reduce seizure (...) an alternative. There has been widespread interest from the public and the media in the medical use of cannabis and its active components (called cannabinoids). The medicinal grade cannabinoid studied in the main trials of this review do not have hallucinogenic effects. Laboratory and animal studies have suggested that cannabinoids might reduce epileptic seizures, and they have shown promise in some studies in people with severe epilepsy. However, there has been concern about the quality of these studies

2019 NIHR Dissemination Centre

11. Pharmacotherapies for cannabis dependence. (Full text)

Pharmacotherapies for cannabis dependence. Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders.This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014.To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive care) for reducing symptoms of cannabis withdrawal and promoting cessation (...) or reduction of cannabis use.We updated our searches of the following databases to March 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and Web of Science.Randomised controlled trials (RCTs) and quasi-RCTs involving the use of medications to treat cannabis withdrawal or to promote cessation or reduction of cannabis use, or both, in comparison with other medications, placebo or no medication (supportive care) in people diagnosed as cannabis dependent or who

2019 Cochrane PubMed

12. Cannabis use in individuals with clinically high-risk (CHR) of psychosis: A comprehensive review

Cannabis use in individuals with clinically high-risk (CHR) of psychosis: A comprehensive review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

13. Cannabis use during opioid substitution treatment: a systematic review

Cannabis use during opioid substitution treatment: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

14. Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning

Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

15. Cannabis in end-of-life care: a review and rationale of current evidence

Cannabis in end-of-life care: a review and rationale of current evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

16. The effects of recreational cannabis use in people with diabetes: a rapid review

The effects of recreational cannabis use in people with diabetes: a rapid review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

17. Prevalence of cannabis withdrawal in cannabis users: a systematic review and meta-analysis

Prevalence of cannabis withdrawal in cannabis users: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

18. Prevalence of cannabis use during pregnancy: a systematic review

Prevalence of cannabis use during pregnancy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

19. Risks of harm with cannabinoids, cannabis and cannabis-based medicine for pain management relevant to patients receiving pain treatment: Protocol for an overview of systematic reviews

Risks of harm with cannabinoids, cannabis and cannabis-based medicine for pain management relevant to patients receiving pain treatment: Protocol for an overview of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

20. Cannabis for management of chronic cancer-related pain: a systematic review and meta-analysis

Cannabis for management of chronic cancer-related pain: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO